Welcome to our dedicated page for Definitive Healthcare news (Ticker: DH), a resource for investors and traders seeking the latest updates and insights on Definitive Healthcare stock.
Definitive Healthcare Corp. (NASDAQ: DH) is a leading provider of healthcare commercial intelligence, specializing in delivering comprehensive data and analytics on healthcare providers and their activities. The company’s suite of solutions offers clients access to the most accurate and detailed information available, covering over 8,100 hospitals and Integrated Delivery Networks (IDNs), 7,300 ambulatory surgery centers, 11,000 imaging centers, 38,000 long-term care facilities, 1,200 Accountable Care Organizations (ACOs) and Health Information Exchanges (HIEs), 197,000 physician groups, 1.3 million physicians, and 750 Canadian hospitals.
Definitive Healthcare's robust data set helps organizations in the healthcare sector optimize everything from product development to go-to-market planning, and sales and marketing execution. Backed by Spectrum Equity, the company is committed to transforming data, analytics, and expertise into actionable healthcare commercial intelligence.
The company continually invests in enhancing its product offerings and expanding its data coverage. Recent achievements include a 14% year-over-year revenue growth in the third quarter, reaching $65.3 million. Additionally, Definitive Healthcare has forged strategic partnerships, such as the recent collaboration with VML Health to streamline engagement between pharmaceutical companies and Key Opinion Leaders (KOLs), leveraging the Monocl ExpertInsight platform.
Definitive Healthcare’s competitive edge lies in its ability to provide unparalleled insights into the healthcare provider market, which equips its clients with the necessary tools to identify and capitalize on new opportunities. The company’s platform supports clients in uncovering the right markets, opportunities, and individuals, thereby shaping the future of healthcare. With the majority of its revenue derived from the United States, Definitive Healthcare continues to be a pivotal player in the healthcare data analytics industry.
For more information, visit www.definitivehc.com.
Definitive Healthcare (Nasdaq: DH) has launched the Passport Analytics Suite, designed to enhance the efficiency of life sciences organizations in product development and commercialization. Powered by technologies from the recently acquired Analytical Wizards, the suite includes Passport Promotional Analytics and Passport Planning & Performance. These tools enable clients to optimize brand performance, marketing strategies, and product planning by integrating diverse data sources. This innovation positions Definitive Healthcare as a leader in offering comprehensive, data-agnostic analytics solutions.
Definitive Healthcare Corp. (Nasdaq: DH) has announced its participation in two key conferences in March 2022. The company will present at the Raymond James 43rd Annual Institutional Investors Conference on March 7 at 1:05 PM ET, featuring CEO Jason Krantz and CFO Rick Booth. Additionally, they will present at the Deutsche Bank 30th Annual Media, Internet & Telecom Conference on March 14 at 10:20 AM ET, with President Robert Musslewhite and CFO Booth. Both events will be webcast live, with replays available later.
Definitive Healthcare reported a 38% increase in Q4 2021 revenue to $46.3 million, while full-year revenue grew 40% to $166.2 million. Despite a GAAP net loss of $(14.8) million in Q4, adjusted net income rose to $6.6 million. Adjusted EBITDA in Q4 was $13.1 million, or 28% of revenue. For 2022, the company projects revenue between $218 million and $222 million. Key highlights include significant new contracts with major healthcare companies and the launch of a new product, Latitude Reporting.
Definitive Healthcare (Nasdaq: DH) will report its Q4 and full year 2021 financial results on February 23, 2022, post-market close. The company will also host a conference call and webcast at 5:00 PM ET to discuss these results. Investors can access the live audio webcast via the Investor Relations website. A replay of the call will be available shortly after its conclusion and will remain accessible until March 9, 2022. Definitive Healthcare specializes in healthcare commercial intelligence, leveraging data and analytics for market success.
Definitive Healthcare (Nasdaq: DH) launched Latitude Discovery on January 25, 2022, aimed at aiding pre-commercial biopharma and medical device companies. This innovative tool allows users to perform iterative analyses of real-world data to evaluate market opportunities linked to therapy development. Latitude Discovery provides self-service access to extensive market intelligence, enabling efficient cohort creation and real-time commercial intelligence visualizations. This product is part of the Latitude Analytics Suite, enhancing companies' commercialization efforts with precise analytics.
Definitive Healthcare Corp. (Nasdaq: DH) has announced its inclusion in the Russell 1000® Index, effective from December 20, 2021. This milestone aims to enhance the company's visibility to investors and broaden its shareholder base. CEO Jason Krantz expressed optimism about this change, stating it enables the introduction of healthcare commercial intelligence to a wider audience, helping businesses succeed in the complex healthcare market.
Definitive Healthcare Corp. (Nasdaq: DH) announced that CEO Jason Krantz and CFO Rick Booth will present at the Barclays Virtual Global Technology, Media and Telecommunications Conference on December 7, 2021, at 9:45 a.m. Eastern Time. The live presentation will be accessible via the investor relations page of Definitive Healthcare's website, with a limited-time replay available afterward. Definitive Healthcare specializes in healthcare commercial intelligence, providing a SaaS platform to help clients identify market opportunities and drive commercial success.
Definitive Healthcare Corp. (Nasdaq: DH) has successfully closed its underwritten public offering of 11 million shares of Class A common stock at $36.00 per share. Underwriters hold a 30-day option for an additional 1.65 million shares. Proceeds will fund acquisitions and general corporate purposes, including buying 7 million limited liability interests from AIDH TopCo, LLC, and repurchasing 2.23 million shares of its Class A stock. Goldman Sachs and J.P. Morgan led the offering with support from Morgan Stanley and Barclays.
Definitive Healthcare Corp. (Nasdaq: DH) announced a public offering of 11 million shares of its Class A common stock at $36.00 per share. The offering includes a 30-day option for underwriters to purchase an additional 1.65 million shares. Closing is anticipated on November 22, 2021. Proceeds will fund acquisitions and general corporate purposes, such as buying 7 million limited liability interests from its subsidiary and repurchasing 2.23 million Class A shares. The offering is managed by Goldman Sachs & Co. and J.P. Morgan among others.
Definitive Healthcare Corp. (Nasdaq: DH) has initiated a public offering of 11,000,000 shares of its Class A common stock, with an option for underwriters to acquire an additional 1,650,000 shares. The net proceeds will fund acquisitions and general corporate purposes, including purchasing up to 7,000,000 limited liability interests from its subsidiary, AIDH TopCo, LLC, and repurchasing up to 2,233,238 shares of Class A stock. The offering is managed by leading financial firms, with a prospectus available through the SEC.
FAQ
What is the current stock price of Definitive Healthcare (DH)?
What is the market cap of Definitive Healthcare (DH)?
What services does Definitive Healthcare Corp. provide?
How does Definitive Healthcare’s data benefit its clients?
What is the geographic focus of Definitive Healthcare’s revenue?
Who backs Definitive Healthcare Corp.?
What recent financial achievement has Definitive Healthcare reported?
What recent partnerships has Definitive Healthcare formed?
What types of healthcare providers are included in Definitive Healthcare’s data?
How does Definitive Healthcare stay competitive in the market?
What is the Monocl ExpertInsight platform used for?
Where can I find more information about Definitive Healthcare?
